about
A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode PsychosisCommunity alternatives to acute inpatient care for severe psychiatric patients.The early phases of anxiety disorders: from prevention to treatment.Cross-Modal Recruitment of Auditory and Orofacial Areas During Sign Language in a Deaf Subject.Disability multilevel modelling in first episodes of psychosis at 3-year follow-up.Deep brain stimulation and treatment-resistant obsessive-compulsive disorder: A systematic review.Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis.Main determinants of Global Assessment of Functioning score in schizophrenia: a European multicenter study.Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.Recovery of long-term paresis following resection of WHO grade II gliomas infiltrating the pyramidal pathway.Variations in Disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis.Effect of DISC1 polymorphisms on the long-term course of neurocognitive deficits in non-affective psychosis.Incorporating local information and prior expert knowledge to evidence-informed mental health system researchThe feasibility of applying the clinical staging paradigm to the care of people with mental disordersObsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case reportCatechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosisDrug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivoAge of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-upThe synergetic effect of childhood trauma and recent stressful events in psychosis: associated neurocognitive dysfunctionEffect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal studyDissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohortData regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosisDopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychoticsLong-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and ZiprasidoneDifferences between psychiatric disorders in the clinical and functional effectiveness of an acute psychiatric day hospital, for acutely ill psychiatric patientsAssociation of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic TreatmentCannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients
P50
Q33620395-06CEF59D-FC12-4AA8-84B2-4C82732453F0Q38061033-CE5AD0B2-841F-45D4-90F3-C983FCF6CB11Q38250009-3C8BA85E-CF46-4ED9-A0D0-6854A883398FQ38375713-99EA40BF-E1CB-4A89-B32B-3FDCE842BD30Q39035147-3A3127C2-C281-4DB2-BA68-B23C110E76F0Q39414091-7C395C8D-51D0-4EC8-B2DC-D6CA95CA01DFQ43209639-BAB45090-6A3A-4D1B-AD82-25EF605A6778Q45206796-F726FBCA-FE60-41B6-99F3-B3F202925ECEQ47587816-C5EAC2E4-352F-416B-8FE6-2C21CEFF935EQ47619757-91FC9A34-A576-414F-8F8E-14DA35C1B910Q48154415-CCBCA973-9327-46B7-A576-37BE4BEEA2F4Q50435936-AC1F9B37-63BF-4461-A39B-193B7DF55C80Q58231107-9F2CBC7D-307E-4F8A-8FE7-C9A496996359Q58231114-D5CBFD1F-6344-4EBA-9F15-88E4E48B79DEQ60446393-0E72FE31-594E-4AFD-AE51-454619855D6EQ60446395-7B507A4D-521C-4672-9494-8BE8B9AF1B62Q64062883-4DEAC34B-91F3-4686-B503-EC1C40E26936Q88964845-D8EF7C4A-F2E6-48B9-BEFA-F8DBF56A9180Q90746761-8DF6E6EF-EDD8-4B9B-9DC1-2BD1BB40FF02Q91290103-D8C7CE6E-2C7E-48A3-BFB9-DD3356DB5A3AQ91315187-BFD2A55F-0B79-474F-8AE0-EA67643B3E9FQ91319800-35DC2A26-779A-42F5-BCCE-AFC0FF8BCAF8Q91329821-0BE307B5-C81D-4C2F-99B5-C75C8F33C3EFQ91445637-7E0FC81D-2398-4983-AC42-EBF12D1932FBQ92499815-75728022-055C-475D-97D0-9E19B448067FQ92818080-D61C082F-DE0A-46B5-8B6F-6B02D7400D3BQ92954522-512B3366-2111-4BED-BC05-F55C6E660CC5
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5478-3376
@en
name
Javier Vázquez-Bourgon
@ast
Javier Vázquez-Bourgon
@en
Javier Vázquez-Bourgon
@es
Javier Vázquez-Bourgon
@nl
type
label
Javier Vázquez-Bourgon
@ast
Javier Vázquez-Bourgon
@en
Javier Vázquez-Bourgon
@es
Javier Vázquez-Bourgon
@nl
prefLabel
Javier Vázquez-Bourgon
@ast
Javier Vázquez-Bourgon
@en
Javier Vázquez-Bourgon
@es
Javier Vázquez-Bourgon
@nl
P106
P1153
15038677900
P21
P31
P496
0000-0002-5478-3376